Skip to main content
Top
Published in: International Cancer Conference Journal 1/2017

01-01-2017 | Case report

A case of metastatic renal cell carcinoma showing complete remission after cytoreductive nephrectomy followed by temsirolimus

Authors: Naotaka Nishiyama, Naoya Masumori

Published in: International Cancer Conference Journal | Issue 1/2017

Login to get access

Abstract

Here, we present a case report of a patient with poor-risk advanced renal cell carcinoma who had a complete remission after cytoreductive nephrectomy followed by temsirolimus. A 67-year-old woman was diagnosed with advanced renal cell carcinoma, stage pT3aN2M1 in April 2013. In the Memorial Sloan-Kettering Cancer Center criteria, she had three prognostic factors and was classified into the poor-risk category. After 23 weeks of treatment with temsirolimus, complete remission was achieved. Temsirolimus treatment was discontinued after 23 weeks because of grade 3 toxicity noninfectious pneumonitis. Five months after beginning steroid treatment without temsirolimus, a CT scan showed no new metastatic lesion or progression of disease. This was a very rare case with achievement of a complete remission after cytoreductive nephrectomy followed by temsirolimus.
Literature
1.
go back to reference Santoni M, De Tursi M, Felici A et al (2013) Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther 13:697–709CrossRefPubMed Santoni M, De Tursi M, Felici A et al (2013) Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther 13:697–709CrossRefPubMed
2.
go back to reference Hudes G, Carducci M, Tomczak P et al (2007) Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMed Hudes G, Carducci M, Tomczak P et al (2007) Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMed
5.
go back to reference Miyake H, Harada K, Kumano M et al (2014) Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan. Int J Clin Oncol. 19:679–685CrossRefPubMed Miyake H, Harada K, Kumano M et al (2014) Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan. Int J Clin Oncol. 19:679–685CrossRefPubMed
6.
go back to reference Sun Y, Rha S, Lee SH et al (2012) Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol 42:836–844CrossRefPubMed Sun Y, Rha S, Lee SH et al (2012) Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol 42:836–844CrossRefPubMed
7.
go back to reference Dabydeen DA, Jagannathan JP, Ramaiya N et al (2012) Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 48:1519–1524CrossRefPubMed Dabydeen DA, Jagannathan JP, Ramaiya N et al (2012) Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 48:1519–1524CrossRefPubMed
8.
go back to reference Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540PubMed Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540PubMed
9.
go back to reference Mekhail TM, Abou-Jawde RM, Boumerhi G et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832–841CrossRefPubMed Mekhail TM, Abou-Jawde RM, Boumerhi G et al (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832–841CrossRefPubMed
10.
go back to reference Afshar M, Pascoe J, Whitmarsh S et al (2014) Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center. Drug Des Devel Ther. 17:13–19CrossRef Afshar M, Pascoe J, Whitmarsh S et al (2014) Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center. Drug Des Devel Ther. 17:13–19CrossRef
11.
go back to reference Ueda K, Suekane S, Mitani T et al (2016) Spontaneous regression of multiple pulmonary nodules in a patient with unclassified renal cell carcinoma following laparoscopic partial nephrectomy: a case report. Mol Clin Oncol. 5:49–52PubMedPubMedCentral Ueda K, Suekane S, Mitani T et al (2016) Spontaneous regression of multiple pulmonary nodules in a patient with unclassified renal cell carcinoma following laparoscopic partial nephrectomy: a case report. Mol Clin Oncol. 5:49–52PubMedPubMedCentral
12.
go back to reference Nakajima T, Suzuki M, Ando S et al (2006) Spontaneous regression of bone metastasis from renal cell carcinoma; a case report. BMC Cancer 13(6):11CrossRef Nakajima T, Suzuki M, Ando S et al (2006) Spontaneous regression of bone metastasis from renal cell carcinoma; a case report. BMC Cancer 13(6):11CrossRef
13.
go back to reference Atkinson BJ, Cauley DH, Ng C et al (2014) Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 113:376–382CrossRefPubMed Atkinson BJ, Cauley DH, Ng C et al (2014) Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 113:376–382CrossRefPubMed
14.
go back to reference Weichhart T, Hengstschläger M, Linke M (2015) Regulation of innate immune cell function by mTOR. Nat Rev Immunol 15:599–614CrossRefPubMed Weichhart T, Hengstschläger M, Linke M (2015) Regulation of innate immune cell function by mTOR. Nat Rev Immunol 15:599–614CrossRefPubMed
Metadata
Title
A case of metastatic renal cell carcinoma showing complete remission after cytoreductive nephrectomy followed by temsirolimus
Authors
Naotaka Nishiyama
Naoya Masumori
Publication date
01-01-2017
Publisher
Springer Japan
Published in
International Cancer Conference Journal / Issue 1/2017
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0261-y

Other articles of this Issue 1/2017

International Cancer Conference Journal 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine